Edwards Lifesciences CorporationEWNYSE
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank28
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P28
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -21.40% |
| Q3 2025 | 97.69% |
| Q2 2025 | 3.50% |
| Q1 2025 | 319.92% |
| Q4 2024 | -136.24% |
| Q3 2024 | -5.30% |
| Q2 2024 | 794.39% |
| Q1 2024 | -139.17% |
| Q4 2023 | -66.80% |
| Q3 2023 | 1124.70% |
| Q2 2023 | -89.30% |
| Q1 2023 | 11.07% |
| Q4 2022 | -8.74% |
| Q3 2022 | -6.71% |
| Q2 2022 | 13.26% |
| Q1 2022 | -21.49% |
| Q4 2021 | -29.76% |
| Q3 2021 | 1.10% |
| Q2 2021 | 75.07% |
| Q1 2021 | -24.88% |
| Q4 2020 | 85.10% |
| Q3 2020 | -6.53% |
| Q2 2020 | 11.69% |
| Q1 2020 | -48.17% |
| Q4 2019 | -8.67% |
| Q3 2019 | 28.17% |
| Q2 2019 | 22646.67% |
| Q1 2019 | -99.49% |
| Q4 2018 | -14.40% |
| Q3 2018 | 144.15% |
| Q2 2018 | -7.34% |
| Q1 2018 | -58.42% |
| Q4 2017 | 17.08% |
| Q3 2017 | 57.21% |
| Q2 2017 | 54.09% |
| Q1 2017 | -36.20% |
| Q4 2016 | -2.33% |
| Q3 2016 | 8.20% |
| Q2 2016 | 77.68% |
| Q1 2016 | 3.18% |